O uso da Buprenorfina Sublingual (TEMGESIC) no Alívio da Dor em Pacientes com Câncer. Um Estudo em 32 Doentes
In order to evaluate control of câncer pain under sublingual Buprenorphine (Temgesic), 32 patients were evaluated. The difficulties in measurement of clinical pain intensity are discussed. Three scales were used in the criteria for judging pain intensity. The most common side effects were: nausea in...
| Autor: | |
|---|---|
| Tipo de documento: | artigo |
| Estado: | Versão publicada |
| Data de publicação: | 2023 |
| País: | Brasil |
| Recursos: | Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA) |
| Repositório: | Revista Brasileira de Cancerologia (Online) |
| Idioma: | português |
| OAI Identifier: | oai:rbc.inca.gov.br:article/3157 |
| Acesso em linha: | https://rbc.inca.gov.br/index.php/revista/article/view/3157 |
| Access Level: | Acceso aberto |
| Palavra-chave: | Buprenorfina Dor no Câncer Buprenorphine Cancer Pain |
| Resumo: | In order to evaluate control of câncer pain under sublingual Buprenorphine (Temgesic), 32 patients were evaluated. The difficulties in measurement of clinical pain intensity are discussed. Three scales were used in the criteria for judging pain intensity. The most common side effects were: nausea in 12.5%, vomiting in 21.8%, dizziness in 6.2%, and drowsiness in 15.6%. Of the 7 patients with vomits only 3 did not have the symptom before starting on Temgesic. Therewasnocaseofrespiratorydepression. Drowsiness, more common in patients over 70 years, beneficted from smaíler doses (10 micrograms) at 6 hour intervals instead of full doses of 20 micrograms at 12 hour intervals. The analgesic effect was enhanced by aging; it was excellent in metastatic bone disease, very good in pelvic tumorsand less than satisfàctory in gastric cancer. The sublingual route was appreciated by all patients, compared with previous parenteral use of analgesic drugs. |
|---|